JP2004537275A - D−アミノ酸オキシダーゼおよびd−アスパラギン酸オキシダーゼのアンタゴニストを使用するcns障害の処置 - Google Patents
D−アミノ酸オキシダーゼおよびd−アスパラギン酸オキシダーゼのアンタゴニストを使用するcns障害の処置 Download PDFInfo
- Publication number
- JP2004537275A JP2004537275A JP2002566376A JP2002566376A JP2004537275A JP 2004537275 A JP2004537275 A JP 2004537275A JP 2002566376 A JP2002566376 A JP 2002566376A JP 2002566376 A JP2002566376 A JP 2002566376A JP 2004537275 A JP2004537275 A JP 2004537275A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- dao
- branched
- substituted
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WPDAFVMSJVJZDS-UHFFFAOYSA-N BC(C(CS(CC1)=O)N1[AlH2])=O Chemical compound BC(C(CS(CC1)=O)N1[AlH2])=O WPDAFVMSJVJZDS-UHFFFAOYSA-N 0.000 description 1
- PAQVZKIXMHJEBY-UHFFFAOYSA-N BC(C(CSCC1)N1[AlH2])=O Chemical compound BC(C(CSCC1)N1[AlH2])=O PAQVZKIXMHJEBY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26188301P | 2001-01-16 | 2001-01-16 | |
US30544501P | 2001-07-13 | 2001-07-13 | |
US34521101P | 2001-10-22 | 2001-10-22 | |
US33388101P | 2001-11-19 | 2001-11-19 | |
PCT/IB2002/001262 WO2002066672A2 (en) | 2001-01-16 | 2002-01-15 | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004537275A true JP2004537275A (ja) | 2004-12-16 |
JP2004537275A5 JP2004537275A5 (pt) | 2006-01-05 |
Family
ID=27500728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002566376A Pending JP2004537275A (ja) | 2001-01-16 | 2002-01-15 | D−アミノ酸オキシダーゼおよびd−アスパラギン酸オキシダーゼのアンタゴニストを使用するcns障害の処置 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1412515A2 (pt) |
JP (1) | JP2004537275A (pt) |
KR (1) | KR20030066813A (pt) |
CN (1) | CN1568370A (pt) |
AU (1) | AU2002247939B2 (pt) |
BR (1) | BR0206495A (pt) |
CA (1) | CA2433866A1 (pt) |
EA (1) | EA006654B1 (pt) |
IL (1) | IL156865A0 (pt) |
MX (1) | MXPA03006321A (pt) |
WO (1) | WO2002066672A2 (pt) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009522377A (ja) * | 2006-01-09 | 2009-06-11 | オクラホマ メディカル リサーチ ファウンデーション | 炎症性疾患治療のためのランチオニン関連化合物 |
JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | D−アスパラギン酸オキシダーゼおよびd−アミノ酸オキシダーゼに対する新規阻害剤 |
JP2012515720A (ja) * | 2009-01-20 | 2012-07-12 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE408593T1 (de) | 2001-05-03 | 2008-10-15 | Galileo Lab Inc | Pyruvatderivate |
EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
WO2003039540A2 (en) * | 2001-11-09 | 2003-05-15 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
US20060234221A1 (en) * | 2001-12-12 | 2006-10-19 | Genset S.A. | Biallelic markers of d-amino acid oxidase and uses thereof |
EP1495041A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA interferon-mediated inhibition of gene expression of G72 and D-amino acid oxidase (DAAO) using short-term interfering nucleic acid (siNA) |
GB0223424D0 (en) * | 2002-10-09 | 2002-11-13 | Imp College Innovations Ltd | Disease-associated gene |
BRPI0418244A (pt) | 2003-12-29 | 2007-04-17 | Sepracor Inc | composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
GB2456390A (en) * | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
WO2012135119A1 (en) * | 2011-03-25 | 2012-10-04 | Genomind, Llc | Biomarker-based detection and treatment of neurodegenerative depression |
EP2831232A4 (en) | 2012-03-30 | 2015-11-04 | Univ Washington | METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM |
RU2765625C2 (ru) | 2016-06-13 | 2022-02-01 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
EP3468944B1 (en) | 2016-06-13 | 2022-11-16 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
CN108504752B (zh) * | 2018-06-26 | 2021-05-11 | 华中农业大学 | 一种与母猪繁殖性状关联的分子标记及应用 |
CN111909907B (zh) * | 2020-07-08 | 2022-05-24 | 浙江工业大学 | 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
CA2361408A1 (en) * | 1999-03-30 | 2000-10-05 | Genset S.A. | Schizophrenia associated genes, proteins and biallelic markers |
AU6462500A (en) * | 1999-07-29 | 2001-02-19 | Patrick T. Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
-
2002
- 2002-01-15 WO PCT/IB2002/001262 patent/WO2002066672A2/en active Application Filing
- 2002-01-15 AU AU2002247939A patent/AU2002247939B2/en not_active Ceased
- 2002-01-15 MX MXPA03006321A patent/MXPA03006321A/es unknown
- 2002-01-15 JP JP2002566376A patent/JP2004537275A/ja active Pending
- 2002-01-15 EP EP02717019A patent/EP1412515A2/en not_active Withdrawn
- 2002-01-15 CA CA002433866A patent/CA2433866A1/en not_active Abandoned
- 2002-01-15 CN CNA028066650A patent/CN1568370A/zh active Pending
- 2002-01-15 KR KR10-2003-7009412A patent/KR20030066813A/ko not_active Application Discontinuation
- 2002-01-15 BR BR0206495-2A patent/BR0206495A/pt not_active IP Right Cessation
- 2002-01-15 EA EA200300807A patent/EA006654B1/ru not_active IP Right Cessation
- 2002-01-15 IL IL15686502A patent/IL156865A0/xx unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009522377A (ja) * | 2006-01-09 | 2009-06-11 | オクラホマ メディカル リサーチ ファウンデーション | 炎症性疾患治療のためのランチオニン関連化合物 |
JP2012515720A (ja) * | 2009-01-20 | 2012-07-12 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 |
JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | D−アスパラギン酸オキシダーゼおよびd−アミノ酸オキシダーゼに対する新規阻害剤 |
JP2010254609A (ja) * | 2009-04-23 | 2010-11-11 | Kitasato Institute | D−アスパラギン酸オキシダーゼおよびd−アミノ酸オキシダーゼに対する新規阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
AU2002247939B2 (en) | 2007-01-25 |
MXPA03006321A (es) | 2003-10-06 |
BR0206495A (pt) | 2006-01-24 |
CN1568370A (zh) | 2005-01-19 |
WO2002066672A3 (en) | 2004-02-26 |
IL156865A0 (en) | 2004-02-08 |
CA2433866A1 (en) | 2002-08-29 |
KR20030066813A (ko) | 2003-08-09 |
EA200300807A1 (ru) | 2004-08-26 |
EA006654B1 (ru) | 2006-02-24 |
AU2002247939B9 (en) | 2002-09-04 |
EP1412515A2 (en) | 2004-04-28 |
WO2002066672A2 (en) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002247939B2 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
AU2002247939A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
WO2003047558A2 (en) | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors | |
Hirano et al. | Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? | |
US11549145B2 (en) | Methods and compositions for inhibiting and treating neurological conditions | |
JP4018884B2 (ja) | 脊柱筋萎縮症の治療 | |
Siuciak et al. | Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function | |
Huppke et al. | Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia | |
Wang et al. | Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions | |
Vannucchi et al. | Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats | |
Aiello et al. | Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension | |
US20080146540A1 (en) | Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association | |
US20100267626A1 (en) | Methods and compositions for measuring wnt activation and for treating wnt-related cancers | |
EP2933265B1 (en) | Pharmacological chaperones for treating obesity | |
WO2005007144A2 (en) | Method of diagnosis and treatment for asthma based on haplotype association | |
Fraiberg et al. | Genetic defects of autophagy linked to disease | |
Loureiro et al. | N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor | |
JP2004504053A (ja) | 肥満症の治療および/または予防に好適である化合物の発見法 | |
US20220162610A1 (en) | Novel rna transcript | |
Reed et al. | Discovery of VU6027459: a first-in-class selective and CNS penetrant mGlu7 positive allosteric modulator tool compound | |
Prieto-Alamo et al. | Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I | |
US20220331333A1 (en) | Rhoa pathway inhibitor in the treatment of neurodevelopmental disorder or neuropsychiatric disorder | |
US6573300B2 (en) | Hydroxyurea treatment for spinal muscular atrophy | |
Morse et al. | Pharmacogenetics of cocaine: a critical review | |
Siegmund et al. | Clinical aspects of inflammatory bowel disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080214 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |